Search results
Showing 991 to 1005 of 1305 results for long term conditions
O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)
NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .
NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .
Psychosis and schizophrenia in children and young people: recognition and management (CG155)
This guideline covers recognising and managing psychosis and schizophrenia in children and young people. It aims to improve early recognition of psychosis and schizophrenia so that children and young people can be offered the treatment and care they need to live with the condition.
Axonics sacral neuromodulation system for faecal incontinence (MIB259)
NICE has developed a medtech innovation briefing (MIB) on Axonics sacral neuromodulation system for faecal incontinence .
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.
Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (HTG553)
Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke.
Evidence-based recommendations on single-port laparoscopic nephrectomy. This involves removing the kidney using several small incisions (laparoscopy).
View recommendations for HTG278Show all sections
Sections for HTG278
Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea (HTG455)
Evidence-based recommendations on hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea in adults. This involves implanting a device under the skin in the chest and connecting it to a nerve under the tongue (hypoglossal nerve).
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.
This manual sets out the process for how new guidance topics and updates to existing NICE guidance are identified, prioritised and routed at NICE, and the decision-making framework used by the NICE prioritisation board
This quality standard covers diagnosis of pancreatic cancer and management of pancreatic ductal adenocarcinoma in adults aged over 18. This quality standard describes high-quality care in priority areas for improvement. It does not cover national initiatives, such as cancer screening or audit.
View quality statements for QS177Show all sections
Sections for QS177
- Quality statements
- Quality statement 1: Specialist pancreatic cancer multidisciplinary teams
- Quality statement 2: Staging using FDG-PET/CT
- Quality statement 3: Resectional surgery
- Quality statement 4: Pancreatic enzyme replacement therapy
- Quality statement 5 (placeholder): Effective interventions to address psychological needs
- Update information
- About this quality standard